Drug development

#Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #Preclinical #RNA #Stem cells

Researchers ID new target in drive to improve immunotherapy for head and neck cancer

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. A study in mice found that using an anti-PD1 immunotherapy… Read More

#Cancer Research #News

#Analysis #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #High throughput screening #Imaging #Mass spectrometry / NMR #Microbiology #Screening #System biology #Target validation

Avacta updates on clinical validation of Adeptrix COVID-19 diagnostic test

Image: Pille-Riin Priske Avacta has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Business #Drug development #Drug discovery #Enabling technologies #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA #Stem cells

GSK and CureVac in mRNA technology collaboration

27 July 2020 Image: CDC GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical trials #Computational chemistry #Drug development

Cytel makes access to clinical trial designs easier

24 July 2020 Image: Joshua Sortino Cytel’s East Alloy platform is a web-native extension of the company’s East software for adaptive clinical trial design and analysis. By leveraging the speed of cloud computing and the pace of SaaS delivery, East Alloy enables easy implementation of computationally intensive Bayesian… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News

#Assay development optimisation & technology #Business #Drug development #Drug discovery #Drug targets #High throughput screening #Immunology #Lead discovery #Screening #Stem cells #Therapeutics

AbCellera agreement to use humanised mice platform for antibody discovery

21 July 2020 Image: Henry Lai AbCellera has entered into an agreement with Alloy Therapeutics to use the ATX-Gx humanised mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #RNA #Stem cells

Study shows Oxford coronavirus vaccine produces strong immune response

A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News

#Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Lead discovery #Regulatory

Phase 1 clinical trial of COVID-19 vaccine begins at University of Queensland

The next critical phase for The University of Queensland’s (UQ) COVID-19 vaccine is underway, with the research effort moving out of the lab and into human trials. Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist,… Read More

#Covid-19 #News

#Cell therapy #Drug development #Drug discovery #Gene therapy #High Content Screening #Lead discovery #Oncology #RNA

New research model for Cancer Research UK following £300M drop in income

Cancer Research UK is planning to become a leaner, more focused organisation following the impact of COVID-19 on its fundraising income. The charity is making difficult decisions to reduce how much it spends on beating cancer, its operations and the number of staff following… Read More

#Covid-19 #News

#Academic #Analysis #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #Pharmacology #Screening #System biology #Systems biology #Therapeutics

Remotely accessible assays help researchers work from home

Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their R&D,… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell culture #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Merck opens its largest M Lab Collaboration Centre in Shanghai

14 July 2020 Image: Denys Nevozhai Merck has opened its M Lab Collaboration Centre in Shanghai, the largest of the company’s nine centres worldwide. “With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including… Read More

#News